Ep. 369 - ASCO advances, China innovation & U.S. science under threat
From BioCentury This Week · · 39 min
This plays from the publisher's own server. We do not host a copy.
Description
Revolution Medicines continues to impress with more pancreatic cancer data, earning a standing ovation at ASCO over the weekend. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the detailed data for the company’s daraxonrasib, Akeso’s Harmoni-6 readout, as well as other results from the meeting. BioCentury’s analysts then argue (https://www.biocentury.com/article/659600) that U.S. biotech executives and policymakers should embrace the challenges and opportunities that come with the rise of innovation in China — rather than sticking their heads in the sand. They also discuss (https://www.biocentury.com/article/659615) why leaders of the U.S.’s biggest drug companies should use their influence to stop an OMB proposal that threatens the foundations of U.S. science. Plus: takeaways (https://www.biocentury.com/article/659601) from BioCentury's conversation with Alkermes CEO Richard Pops on The BioCentury Show.
View full story: https://www.biocentury.com/article/659629
#ASCO #PancreaticCancer #BiotechInnovation #ChinaBiotech #DrugDevelopment
00:00 - Introduction 01:49 - ASCO: RevMed 06:50 - ASCO: Akeso 16:33 - China U.S. Biotech Rivalry 24:15 - Science Under Threat 36:29 - Richard Pops Takeaways
To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.
Reach us by sending a text (https://www.buzzsprout.com/1035190/fan_mail/new)